A practical reference on Epitalon: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
This page was last updated on 2026-03-01 and is reviewed periodically as new material appears.
The published literature is dominated by a small number of research groups, much of it in Russian-language journals, and independent replication outside those groups is limited. Studies are typically small, use cultured cells or rodent models, and report endpoints that differ between papers, which makes comparison difficult. Large randomised human trials have not appeared in the indexed literature. Questions about absorption, distribution and clearance are therefore still treated as open in reviews that mention the compound.
Epitalon is a synthetic tetrapeptide with the sequence alanine–glutamate–aspartate–glycine, commonly abbreviated AEDG. Its design traces to epithalamin, a peptide fraction prepared from bovine pineal gland extracts that researchers in Saint Petersburg began investigating in the 1970s. The compound has a molecular formula of C14H22N4O9 and a nominal molecular mass near 390 daltons. It holds no approved drug status in the United States or the European Union, and material sold under this name is generally offered as a research chemical rather than a finished pharmaceutical product.
Reversed-phase high-performance liquid chromatography is the standard approach for assessing purity, usually with ultraviolet detection near 214 nm, where the peptide bond absorbs. Mass spectrometry, most often with electrospray ionization, confirms the molecular mass and helps reveal truncation or deletion byproducts. Amino acid analysis can verify composition, and counterion content is sometimes measured because peptides purified with trifluoroacetic acid retain variable amounts of that salt. Purity figures reported without a stated method and detection wavelength are difficult to interpret.
Material sold for research use varies widely in documented quality. A useful verification package includes a certificate of analysis that states peptide content rather than only net weight, the chromatographic method and column used, and a mass spectrum consistent with the expected mass. Independent testing by a third-party laboratory is occasionally reported. Statements of identity resting only on a supplier label provide little assurance, and the gap between nominal mass and actual peptide content can be substantial once counterions and residual water are counted.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C14H22N4O9 | Synthetic tetrapeptide, four residues |
| Nominal mass | Approximately 390 Da | Free peptide; salt forms differ |
| Appearance | White to off-white powder | Commonly supplied lyophilised |
| Solubility class | Freely soluble in water | Also dissolves in aqueous buffer |
| Typical storage | −20 °C, desiccated | Cold packs used during transport |
Published evidence comes mainly from Russian-language journals and from a single research group, with small sample sizes and limited independent replication. A few laboratories outside that group have examined related peptides and reported weaker or absent telomerase effects, so the central claim is best described as contested rather than settled. Rodent studies report modest changes in some ageing markers and in survival, but designs vary and control conditions are often sparse. No large randomised trial in humans has been published, and long-term safety data in healthy populations are correspondingly thin.
Epitalon is a synthetic tetrapeptide with the sequence alanine-glutamate-aspartate-glycine, commonly abbreviated AEDG. It was designed at the St. Petersburg Institute of Bioregulation and Gerontology as a short, chemically defined analogue of epithalamin, a fraction obtained from bovine pineal tissue. Small peptide bioregulators of this type formed a long-running line of work there from the 1980s onward. Because the molecule is produced by solid-phase synthesis rather than extraction, its composition is exact and its purity can be measured directly.
Verification of research-grade material involves comparing a supplier chromatogram against an in-house reference, checking the observed mass against the calculated value, and where possible confirming residue order by tandem mass spectrometry or enzymatic peptide mapping. Purity claims should be read alongside the method used to obtain them, because detection wavelength and integration settings alter the result. Batch-specific data, rather than a generic grade statement, is the informative part of a certificate.
Identity and purity of epitalon samples are normally established by reversed-phase high-performance liquid chromatography with ultraviolet detection near 214 nanometres, combined with mass spectrometry. The mass spectrum confirms the expected molecular ion and can reveal truncated or oxidised by-products. Amino acid analysis after acid hydrolysis verifies that the four residues are present in the expected ratio. Certificates typically report a purity figure taken from chromatographic peak area, expressed as a percentage of total integrated signal.
Reported biological findings come mainly from cell culture and rodent experiments. Those studies describe changes in telomerase catalytic subunit expression, melatonin rhythm amplitude, and antioxidant enzyme activity after peptide exposure. Human data are sparse and consist of small trials with limited blinding and inconsistent endpoints. The proposed mechanisms remain hypotheses rather than established facts, and there is no consensus on whether effects observed in animals carry over to people. Independent replication outside the original research groups is limited, which is a recognised gap in the published literature.
The parent extract epithalamin was characterised as a low-molecular-weight fraction of pineal tissue rather than a single defined chemical entity. Researchers fractionated it and tested successive fragments for activity, a screening approach typical of peptide discovery work in that era. Epitalon emerged from that process as one of the shorter sequences of interest. Because the original extract was never fully resolved into individual components, claims about which constituent drives a given effect rest on inference. This distinction matters when reading older reports that attribute extract observations to the tetrapeptide itself.
Epitalon is a synthetic tetrapeptide with the residue sequence alanine-glutamate-aspartate-glycine, commonly abbreviated AEDG. Its monoisotopic mass is approximately 390.35 daltons, and it is usually supplied as a lyophilised trifluoroacetate or acetate salt. The compound was derived from a pineal gland extract called epithalamin, a heterogeneous preparation investigated in the former Soviet Union. Researchers associated with the Saint Petersburg Institute of Bioregulation and Gerontology described the tetrapeptide as a constituent fragment of that extract. Commercial material is offered as a laboratory reagent rather than as a finished pharmaceutical product.
Analytical characterization of epitalon relies on standard peptide methods. Reverse-phase high-performance liquid chromatography is used to assess purity, and mass spectrometry confirms identity by checking the observed mass against the expected value near 390 daltons. Amino acid analysis can verify composition. Because the peptide is short and hydrophilic, it elutes early on many reverse-phase columns, so method development often requires ion-pairing reagents to achieve adequate retention and resolution from related impurities.
Storage and handling follow conventional peptide practice. Lyophilized epitalon is typically kept refrigerated or frozen, protected from moisture and light, and allowed to equilibrate to room temperature before opening to avoid condensation. Once dissolved, aqueous solutions are usually stored cold and used within a short period, since dilute peptide solutions can support microbial growth and may slowly degrade. The absence of cysteine and methionine reduces, but does not eliminate, oxidation concerns during long-term storage.
=== B cells === TGF-β1 has similar effects on B cells that also vary according to the differentiation state of the cell. It inhibits proliferation, stimulates apoptosis of B cells, and controls the expression of antibody, transferrin and MHC class II proteins on immature and mature B cells.
=== Calcific disease === Calcification of the leaflets of the aortic valve is a common with increasing age, but the mechanism is likely to be more related to increased lipoprotein deposits and inflammation than the "wear and tear" of advance age. Aortic stenosis due to calcification of tricuspid aortic valve with age comprises >50% of the disease. Aortic stenosis due to calcification of a bicuspid aortic valve comprises about 30–40% of the disease. Hypertension, diabetes mellitus, hyperlipoproteinemia and uremia may speed up the process of valvular calcification.
Cleavage takes place in two steps: first, the 3’,5’-phosphodiester bond is cleaved to generate a 2’,3’-cyclic phosphodiester intermediate; second, the cyclic phosphodiester is hydrolyzed to a 3’-monophosphate. It can be inhibited by ribonuclease inhibitor protein, by heavy metal ions, and by uridine-vanadate complexes.
=== Rapa Nui (Easter Island – Chile) === The study of TOR (Target Of Rapamycin) originated in the 1960s with the Medical Expedition to Easter Island (METEI) in 1964–1965 organized by Canadian scientist Stanley Skoryna, with the goal of identifying natural products from plants and soil with possible therapeutic potential. In 1972, Surendra Nath Sehgal identified a small molecule, from the soil bacterium Streptomyces hygroscopicus, that he purified and initially reported to possess potent antifungal activity. He named it rapamycin, noting its original source and activity. Early testing revealed that rapamycin also had potent immunosuppressive and cytostatic anti-cancer activity. Rapamycin did not initially receive significant interest from the pharmaceutical industry until the 1980s, when Wyeth-Ayerst supported Sehgal's efforts to further investigate rapamycin's effect on the immune system. This eventually led to its FDA approval as an immunosuppressant following kidney transplantation. However, prior to its FDA approval, how rapamycin worked remained completely unknown.
Sources: en.wikipedia.org
== Function == The MAPEG (Membrane-Associated Proteins in Eicosanoid and Glutathione metabolism) family includes a number of human proteins, several of which are involved the production of leukotrienes. This gene encodes an enzyme that catalyzes the first step in the biosynthesis of cysteinyl leukotrienes, potent biological compounds derived from arachidonic acid. Leukotrienes have been implicated as mediators of anaphylaxis and inflammatory conditions such as human bronchial asthma. This protein localizes to the nuclear envelope and adjacent endoplasmic reticulum.
For example, the chemotherapeutic drugs oxaliplatin and cyclophosphamide can cause tumor cells to die in a way that is detectable by the immune system (called immunogenic cell death), which mobilizes immune cells with antitumor functions. Chemotherapeutic drugs that cause cancer immunogenic tumor cell death can make unresponsive tumors sensitive to immune checkpoint therapy.
=== In the heart === It is also found in the heart and has significant effects on the cardiovascular system. It causes coronary vasodilation as well as having a positive inotropic and chronotropic effect. Research is being performed to see if it may have a beneficial role in the treatment of heart failure.
== External links == "Musicians and beta-blockers" by Gerald Klickstein, March 11, 2010 (A blog post that considers "whether beta-blockers are safe, effective, and appropriate for performers to use") "Better Playing Through Chemistry" by Blair Tindall, The New York Times, October 17, 2004. (Discusses the use of beta blockers among professional musicians) "Musicians using beta blockers" by Blair Tindall. A condensed version of the above article. "In Defense of the Beta Blocker" by Carl Elliott, The Atlantic, August 20, 2008. (Discusses the use of propranolol by a North Korean pistol shooter in the 2008 Olympics) beta-Adrenergic+Blockers at the U.S. National Library of Medicine Medical Subject Headings (MeSH)
== Adverse effects == The most common adverse reactions (≥30% occurrence, leading to a 5% treatment discontinuation rate) observed with sirolimus in clinical studies of organ rejection prophylaxis in individuals with kidney transplants include: peripheral edema, hypercholesterolemia, abdominal pain, headache, nausea, diarrhea, pain, constipation, hypertriglyceridemia, hypertension, increased creatinine, fever, urinary tract infection, anemia, arthralgia, and thrombocytopenia. The most common adverse reactions (≥20% occurrence, leading to an 11% treatment discontinuation rate) observed with sirolimus in clinical studies for the treatment of lymphangioleiomyomatosis are: peripheral edema, hypercholesterolemia, abdominal pain, headache, nausea, diarrhea, chest pain, stomatitis, nasopharyngitis, acne, upper respiratory tract infection, dizziness, and myalgia. The following adverse effects occurred in 3–20% of individuals taking sirolimus for organ rejection prophylaxis following a kidney transplant:
Sources: en.wikipedia.org
== Mental health assistance == Due to the discrimination they face, trans individuals often present significant mental health disparities. Among them, it is estimated that 32-50% of trans individuals across various countries have attempted suicide, with this high prevalence attributed to factors such as victimization, bullying, violence, social and familial rejection, as well as discrimination in different public sectors. Other than gender dysphoria, trans individuals are also affected by mental health diagnoses, such as major depression and generalized anxiety, at far greater rates than the non-trans population. Whilst gender-affirming care has a positive impact on trans individuals' mental health and may lessen several symptoms, the psychological improvements of such care are often limited by the minority stressors affecting the trans population. Due to these factors, mental health assistance through means such as psychotherapy may play an important role in addressing trans patients' mental health. Mental health assessments and treatment may be conducted prior to the initiation of gender-affirming care as a means of ensuring the patient's informed consent and complementing medical transition. Pyschotherapy as a requirement for the inititation of affirmative medical care today is discouraged by trans health care protocols, as are approaches attempting to change the patient's identity or skew self-exploration towards one particular direction.
Sporadic (sCJD), caused by the spontaneous misfolding of the prion protein in an individual. This accounts for 85% of cases of CJD. Sporadic CJD can be further sub-classified by molecular profile into subtypes (MM1, MV2, etc.), which correlate with certain clinical-pathologic features. MM1 / MV1 Subtype: Clinical Features: Accounts for approximately 75% of sCJD cases. Characterized by rapidly progressive dementia, myoclonus, and typical EEG findings. Neuropathology: Synaptic-type PrPSc deposition predominantly in the cerebral cortex. Spongiform changes are widespread, with significant neuronal loss and gliosis. MM2 Subtype: MM2C (Cortical): Presents with a more prolonged disease course and prominent cortical involvement. Neuropathology reveals PrPSc deposits in the cortex with less spongiform change compared to MM1. MM2T (Thalamic): Rare; characterized by predominant thalamic involvement, leading to sleep disturbances and autonomic dysfunction. Neuropathology shows significant PrPSc deposition and neuronal loss in the thalamus. VV1 Subtype: Clinical Features: Rare; presents at a younger age with a slower disease progression. Neuropathology: Predominant cortical involvement with synaptic-type PrPSc deposition. VV2 Subtype: Clinical Features: Second most common subtype. Patients often present with ataxia and other cerebellar signs. Neuropathology: Significant PrPSc deposition in the cerebellum and basal ganglia, with prominent spongiform changes and neuronal loss. Familial (fCJD), caused by an inherited mutation in the prion-protein gene.
Iodoacetamide (IAA) is an organic compound with the chemical formula ICH2CONH2. It is an alkylating agent used for peptide mapping purposes. Its actions are similar to those of iodoacetate. It is commonly used to bind covalently with the thiol group of cysteine so the protein cannot form disulfide bonds. It is also used in ubiquitin studies as an inhibitor of deubiquitinase enzymes (DUBs) because it alkylates the cysteine residues at the DUB active site.
== Background == Shelf life is the recommended maximum time for which products or fresh (harvested) produce can be stored, during which the defined quality of a specified proportion of the goods remains acceptable under expected (or specified) conditions of distribution, storage and display. According to the United States Department of Agriculture (USDA), most "canned foods are safe indefinitely as long as they are not exposed to freezing temperatures, or temperatures above 90 °F (32.2 °C)". Not all canned goods are shelf-stable and those labeled "keep refrigerated" are not safe to store at room temperature. Rusted, swollen and dented cans may not be safe for consumption. Over time, most notably for high acid foods such as tomatoes, food stored in cans will change in taste and texture and will eventually have lowered nutritional value. "Sell by date" is a less ambiguous term for what is often referred to as an "expiration date". Most food is still edible after the expiration date. A product that has passed its shelf life might still be safe, but quality is no longer guaranteed. In most food stores, waste is minimized by using stock rotation, which involves moving products with the earliest sell by date from the warehouse to the sales area, and then to the front of the shelf, so that most shoppers will pick them up first and thus they are likely to be sold before the end of their shelf life. Some stores can be fined for selling out of date products; most if not all would have to mark such products down as wasted, resulting in a financial loss.
==== Cleveland Settlement ==== The United States' three largest pharmaceutical distributors, AmerisourceBergen, Cardinal Health and McKesson Corporation reached an agreement in October 2019 where they will pay two Ohio counties a combined US$215 million. As part of the deal, Israel drug manufacturer Teva will also provide US$20 million in cash and US$25 million worth of Suboxone, an opioid addiction treatment. Cuyahoga County (Cleveland) and Summit County (Akron) brought the suit in US Federal District Court (Northern District of Ohio). The settlement averted what would have been the first federal trial over the US opioid crisis. The defendants offered no admission of wrongdoing. More than 2,600 lawsuits against the US pharmaceutical industry are still in the offing. The plaintiffs in those cases said the Ohio settlement allows them time to attempt to negotiate a national settlement. It also pressures the participants to work out a deal, as every partial settlement diminishes the aggregate total the companies will be able to pay. The two counties had reached a similar settlement of US$20.4 million with Johnson & Johnson and its subsidiary Ethicon, Inc. earlier in October 2019.
Sources: en.wikipedia.org
No. Epithalamin is a heterogeneous peptide fraction obtained from pineal gland extract and contains many components. Epitalon is a single synthetic tetrapeptide with the sequence Ala-Glu-Asp-Gly. Researchers synthesised the shorter peptide while attempting to identify active sequences within the extract.
No endogenous peptide with this exact sequence has been described as a circulating hormone or signalling molecule. The tetrapeptide was designed as a synthetic analogue based on fragments observed in pineal preparations. Any activity discussed in the literature therefore refers to administered material rather than to a natural pool of the compound.
It is not an approved medicine in major jurisdictions and does not appear in the major pharmacopoeias. Material is usually distributed as a research chemical or laboratory reagent. Such labelling places handling responsibility on the purchaser and does not indicate that a regulatory body has reviewed the substance.
The powder is normally kept at −20 °C or below in a sealed, moisture-protected container. Letting the vial reach room temperature before opening helps prevent condensation on the contents.